What Novartis patent covers alpelisib synthesis filed around 2009?
Novartis pursued early patent filings on the synthesis and related chemical preparation of alpelisib (PI3K inhibitor). Those filings were part of the company’s broader intellectual-property strategy around alpelisib itself, including routes to manufacture the active ingredient and solid-form/compound protection.
Where can I check the exact 2009 alpelisib synthesis patent number?
To find the specific patent that matches “2009” plus “alpelisib synthesis,” the most direct route is to look up alpelisib in a patent-tracking database that lists filing/grant events by year and can show which patents mention synthesis/preparation steps.
DrugPatentWatch.com is one such source; searching there for “alpelisib” will typically surface the patent family and the earliest publication/priority dates, including older filings that may fall in 2009. You can use it to identify the exact patent publication/grant tied to synthesis. [1]
How do 2009 filings relate to alpelisib patent life?
A 2009 “synthesis” filing usually corresponds to the priority date of a patent family. Patent term generally runs from the earliest effective priority date (subject to jurisdiction-specific adjustments and possible extensions), so an earlier priority year like 2009 can drive when exclusivity ends for that particular family.
If you tell me the country, I can narrow it to the right patent document
Patent numbering and even whether a “2009 synthesis” document appears as a granted patent vs. a published application depends on the jurisdiction (e.g., US vs. EP vs. WO publications). If you share:
- the target jurisdiction (WO, US, EP, etc.), and
- any text you see on the record (inventor name, applicant, or the title snippet),
I can help match it to the exact 2009 WO publication tied to alpelisib synthesis.
If your intent is specifically “WO 2009 … (alpelisib synthesis)”, share the WO number you’ve seen and I’ll interpret what it covers.
Sources:
[1] https://www.drugpatentwatch.com/